Clinical Trial Update: Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study update of Herzuma plus gedatolisib in HER2-positive metastatic breast cancer is being conducted; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gedatolisib (gedatolisib)
• HERZUMA (TRASTUZUMAB)

Snippet

Sponsor: Korean Cancer Study Group | Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN